Navigation Links
CBCD Urges Caution in New Herpes Vaccine; Let’s Learn From Side Effects Associated With HPV Vaccine
Date:9/10/2013

Rochester, NY (PRWEB) September 10, 2013

The CBCD urges the medical community to refrain from becoming overly excited by the initiation of phase one human trials in the development of a new herpes vaccine.

The new clinical trial is headed up by Dr. Ian Frazer, who developed and patented the basic technology behind the HPV vaccine against cervical cancer. The vaccine patent was sold to Australian medical company CSL, and later to Merck Pharmaceuticals according to an article published on October 22, 2007 in The Science Times (2).

The medical community should remember that the FDA admits on its website (3) that the HPV vaccine contains DNA fragments. Indeed, the HPV vaccine manufacturing process is not keeping these fragments out. While the FDA believes that foreign DNA fragments are safe, the CBCD believes otherwise.

In fact, The Center believes that the poor safety record of the HPV vaccine, and the large number of people who report side effects (some of them severe), is due to the fragments of foreign DNA contained in it. The CBCD suggests that these foreign DNA fragments could be the cause of the autoimmune conditions observed by Israeli scientists, as suggested by Dr. Hanan Polansky’s Microcompetition with Foreign DNA Theory.

In addition to the concerns raised by the CBCD, leading scientists and health officials from around the world, including Japan, Italy, and Israel are raising serious concerns regarding the safety of the HPV vaccine according to The Japan Times in an article published on June 15, 2013 (4), and an article published in the Israeli newspaper, Haaretz on September 3rd, 2013 (5).

Israeli authors of one recent study on Frazer’s HPV vaccine wrote that there is “evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition.” They further wrote that, “The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry (5).”

The CBCD cautions that using similar methods in the development of a herpes vaccine could have similar, harmful effects.

The CBCD therefore urges the medical community, American health officials, and Dr. Frazer and his team to learn from the past. To ensure true safety, any new herpes vaccine should be free of foreign DNA fragments. Otherwise, the CBCD predicts that the new vaccine will suffer from the same shortcomings that characterize Ian Frazer’s first vaccine.

The CBCD is not against vaccines. The Center is against vaccines that contain foreign DNA.

For more information on the Center for the Biology of Chronic Disease and the dangers posed by foreign DNA, visit http://www.cbcd.net. To request an interview or to speak with a CBCD official, please Email info(at)CBCD(dot)net.

References:

(1)    scirp.org/journal/PaperInformation.aspx?PaperID=36101
(2)    http://www.scribd.com/doc/2670487/Zhou-Jian2
(3)    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm276859.htm
(4)    http://www.japantimes.co.jp/news/2013/06/15/national/cervix-vaccine-issues-trigger-health-notice/#.Ui2EcNJkM_c
(5)    http://www.haaretz.com/news/national/.premium-1.545014

The CBCD is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11107625.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SPIE Encouraged By Increased Science Funding in Obama Budget, Urges Applied Research Emphasis
2. Arnold Schwarzenegger's Climate Change Law Gets Enacted; Going Green News Site Green Bean Cleaning Urges Public to Help It Help Build a Greener Earth
3. SPIE Urges Congress, President to Avoid Fiscal Cliff and Support Science and Technology to Strengthen Economy
4. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
5. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
6. Coalition to Save Pure Files Proxy Documents With SEC, Urges Pures Board to Set an Annual Meeting Date
7. Bed Bugs Rise in Oneida County, My Cleaning Products Cautions Residents and Advises Them to Have a Bed Bug Bully Prepared
8. European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
9. Redbiotec and TeselaGen to Partner on Herpesvirus Vaccine Library
10. SeraCare Introduces New Hepatitis C ACCUVERT Seroconversion Panels and Anti-Herpes ACCUSET Performance Panel
11. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):